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There is a lack of consensus on the pathophysiology of overactive bladder (OAB) and interstitial cystitis/
bladder pain syndrome (IC/BPS). The chronic pain symptoms in IC/BPS and OAB refractory to anti-
muscarinic agents may be due to central nervous system sensitization and persisting abnormalities in the
bladder wall that activate the afferent sensory system. Evidence also indicates that IC/BPS is a hetero-
geneous syndrome and that the two subtypes, the ulcer type (classic) and nonulcer disease, represent
different disease entities. There is a need for noninvasive markers for the differential diagnosis of the
subtypes of IC/BPS and OAB. Increased levels of nerve growth factor (NGF) have been reported in the
bladder tissue and urine of patients with OAB and IC/PBS. Recent studies have also revealed that serum
NGF and C-reactive protein (CRP) are elevated in these two diseases. IC/BPS, but not OAB, involves an
aberrant differentiation program in the bladder urothelium that leads to altered synthesis of several
proteoglycans, cell adhesion and tight junction proteins, and bacterial defense molecules. These ﬁndings
have led to the rationale for identifying urinary biomarkers to detect IC/BPS in patients with frequency
urgency syndrome such as OAB-dry and OAB-wet. Recently, the markers that have been the focus of the
most research are antiproliferative factor, epidermal growth factor, heparin-binding epidermal growth
factor, glycosaminoglycans, and bladder nitric oxide. In addition to these urothelial defense molecules,
inﬂammatory proteins in the urine and serum have been found to possess important roles in the
pathogenesis of IC/BPS and OAB. The urinary proteome is a potential easily accessible source of
biomarkers for differentiation between inﬂammatory bladder disorders. Analysis of multiple urinary
proteins and serum cytokines is a convenient approach to monitoring the activation of inﬂammatory
cells in the bladder tissue. Differences in urinary proteins and serum cytokines might provide a diag-
nostic basis for IC/BPS and could be a tool for the differential diagnosis between IC/BPS and OAB.
Copyright  2012, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic
sterile inﬂammatory disease of the bladder of unknown etiology
characterized by urinary frequency, nocturia, and suprapubic pain
when the bladder is full. Although there are many theories, the
etiology of this condition remains obscure. There is a lack of
consensus on the pathophysiology of IC/BPS. The chronic pain
symptomatology in IC/BPS may be due to central nervous system
sensitization and persisting abnormalities in the urinary bladderBuddhist Tzu Chi General
lien, Taiwan. Tel.: þ886 3
ddhist Compassion Relief Tzu Chithat activate the afferent sensory system [1]. Recent ﬁndings have
proposed several pathophysiologic mechanisms including epithe-
lial dysfunction, activation of mast cells, neurogenic inﬂammation,
autoimmunity, and occult infection. Evidence also indicates that IC/
BPS isaheterogeneoussyndromeand that the twosubtypes, theulcer
type and nonulcer type, represent different disease entities [2]. The
diagnosis of IC/BPS is made by clinical and cystoscopic hydro-
distention and exclusion of other bladder disorders [3]. There is
aneedforanoninvasivemarker fordiagnosing thesubtypesof IC/BPS.
2. Chronic inﬂammation in overactive bladder and interstitial
cystitis/bladder pain syndrome
The clinical presentations of overactive bladder (OAB) and
nonulcer-type IC/BPS are very similar. OAB is considered whenFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Differences in urinary nerve growth factor levels in patients with interstitial cystitis/
bladder pain syndrome, overactive bladder, and control patients [11,52].
Bladder dysfunction Urine
samples
Urinary total
NGF (pg/mL)
Urinary
NGF/Cr
Statistics
Normal control 38 0.46  0.35 0.005  0.003
OAB-responder
Baseline 50 33.3  6.13 1.10  0.26 p < 0.0001a
3 mo 50 17.8  4.31 0.41  0.09 p ¼ 0.008b
OAB-nonresponder
Baseline 20 56.9  19.4 1.38  0.54 p ¼ 0.0001a
3 mo 20 70.57  25.0 1.30  0.46 p ¼ 0.879b
IC/BPS not treated 58 50.1  11.8 0.94  0.23 p < 0.0001a
IC/BPS responders 36 21.3  8.51 0.33  0.09 p ¼ 0.050c
IC/BPS nonresponders 78 46.8  8.92 0.92  018 p ¼ 0.957c
Data are expressed as mean  standard error.
Cr ¼ creatinine; IC/BPS ¼ interstitial cystitis/bladder pain syndrome; NGF ¼ nerve
growth factor.
a Comparison of urinary NGF/Cr level between control and different bladder
dysfunction.
b Comparison of urinary NGF/Cr level between baseline and 3 mo.
c Comparison between IC/BPS not treated and posttreatment.
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incontinence, and it is usually associated with frequency and noc-
turia [4]. Recently, some authors proposed that urothelial
dysfunction, abnormal expression of sensory receptors, abnormal
function of suburothelial interstitial cells, and increased excitability
of detrusor muscles could be the etiologies of OAB [5e7]. IC/BPS,
however, is a chronic inﬂammatory disorder of the urinary bladder
manifested by frequency urgency with or without bladder pain.
Histologically, bladders affected by IC/BPS show inﬁltration of mast
cells, which suggests that the disease is mediated by an abnor-
mality of the immune system [8,9]. Although the International
Continence Society has a clear deﬁnition of urgency, most patients
cannot clearly differentiate urgency from the urge to void. Overlap
and confusion usually exist in the clinical presentations of OAB-dry
and IC/BPS.
3. Potential urine biomarkers for OAB and IC/BPS
Several previous studies have linked OAB and IC/BPS to chronic
inﬂammation of the urinary bladder. Nerve growth factor (NGF) in
urine and bladder tissue, serum cytokines, and serum C-reactive
protein (CRP) have been found to increase in OAB as well as IC/BPS
[10e12]. Previous studies also showed that mast cells are multi-
functional effectors of the immune system, and play an important
role in the pathophysiology of IC/BPS [9]. Because there are simi-
larities in inﬂammatory protein expression between OAB and IC/
BPS, it is possible that there is an inﬂammatory reaction in OAB as
well as in IC/BPS.
4. Urinary NGF in OAB and IC/BPS
Recent studies suggest that the lamina propria of the bladder
plays an important role in transmitting the sensation of bladder
fullness and in the response of the bladder to chemical stimuli and
inﬂammation [5,13,14]. In the urinary tract, NGF is produced by
bladder smooth muscle and urothelium [15]. Previous studies
indicate that NGF is involved in the ongoing regulation of neural
function in conditions such as spinal cord injury and denervation,
as well as in inﬂammation and pain [1,15,16]. Increased levels of
NGF have also been reported in the bladder tissue and urine of
patients with sensory urgency and IC/BPS [10,17]. However, urine
NGF is also increased in several lower urinary tract conditions such
as urinary tract infection, bladder outlet obstruction, and urinary
tract stones [18].
Bladder inﬂammation caused by intravesical instillation of
cyclophosphamide or NGF in rats can induce inﬂammation and lead
to acute afferent nerve activity and long-term plasticity that lowers
the threshold for nociceptive and mechanoceptive afferent ﬁbers
[19e21]. Chronic sensitization of the afferent ﬁbers might involve
both peripheral and central mechanisms. An increase in bladder
NGF in the muscle or urothelium initiates signals that have been
found to transport along the afferent nerves from the bladder to the
dorsal root ganglion or spinal cord [22,23]. A previous study has
shown that intravesical injections of botulinum toxin A (BoNT-A)
can reduce bladder pain in patients with refractory IC/BPS [24]. NGF
levels in the bladder tissue are signiﬁcantly increased in patients
with IC/BPS and decreased to the normal range after BoNT-A
treatment [25].
The clinical symptoms of IC/BPS and OAB are similar, but bladder
pain is typically found in IC/BPS and urgency/urgency incontinence
in OAB. However, patients with IC/BPS usually cannot tolerate a full
bladder and are urged to void to avoid bladder pain. Therefore,
patients with IC/BPS might not characteristically present with
bladder pain but merely have frequency and nocturia, which are
similar to the symptoms of OAB-dry. Although using urinary NGF asa biomarker can be a sensitive molecular diagnostic tool for OAB,
recent research on urinary biomarkers revealed that urinary NGF
levels also increase in patients with IC/BPS [11]. The urinary NGF
levels are closely related to the visual analog scale score for pain
and response to conventional treatment for IC/BPS. Differentiation
of IC/BPS and OAB based on the urinary NGF level is difﬁcult and
does not have a high sensitivity. We need a more detailed analysis
of urinary biomarkers as a noninvasive diagnostic tool for the
differential diagnosis of IC/BPS and OAB. Investigation has shown
that patients with IC/BPS and those with OAB have increased
urinary NGF levels compared with those in control patients
(Table 1). Patients with OAB and IC/BPS who respond to treatment
have decreased urinary NGF levels, whereas those who do not
respond have no change, suggesting both IC/BPS and OAB have
similar pathways related to NGF production.
Histologic investigations of the bladder urothelium and sub-
urothelium have found that chronic inﬂammation is present in 60%
of baseline biopsies of patients with OAB [26]. OAB could be
a subtype of neurogenic inﬂammation characterized by a series of
vascular and nonvascular inﬂammatory responses, triggered by the
activation of primary sensory neurons and the subsequent release
of inﬂammatory neuropeptides, including substance P and calci-
tonin gene-related peptide [27]. These inﬂammatory responses also
induce overexpression of transient receptor potential vanilloid
receptors subfamily type 1 in the suburothelium as well as c-fos
protein in the dorsal root ganglia, which have been demonstrated
in rat models of OAB and in human bladder biopsies [5,14,22].
Chronic inﬂammation has been implicated in the development
of OAB and IC/BPS. Elevated levels of CRP have been associated with
chronic inﬂammation and lower urinary tract symptoms. Serum
CRP levels were signiﬁcantly higher in patients with OAB and IC/
PBS than in control patients. No signiﬁcant difference in CRP levels
was noted between patients with OAB and IC/BPS. In a subgroup
analysis, patients with OAB-wet had higher serum CRP levels than
those with OAB-dry; however, the difference did not reach statis-
tical signiﬁcance [12]. In one study, the serum CRP level was
signiﬁcantly associated with residual urgency in patients with
benign prostatic hyperplasia after medical treatment. The mean
serum CRP level was 0.24 mg/dL (range 0.01e2.84), and residual
urgencywas identiﬁed in 90 patients (43.9%). Patients with residual
urgency were older and had signiﬁcantly higher serum CRP levels
than those without urgency. Patients with serum CRP
levels  0.3 mg/dL had more urgency (82.1%) than those with
serum CRP levels < 0.3 mg/dL (34.9%) [28]. High serum CRP levels
H.-C. Kuo et al. / Tzu Chi Medical Journal 25 (2013) 13e18 15were also found in women with OAB-wet, and they were related to
lowermaximumurinary ﬂow rates and higher bodymass indices in
nonstress urinary incontinence lower urinary tract dysfunction.
Median CRP levels were signiﬁcantly higher in women with OAB-
wet than in women with bladder oversensitivity and the normal
group. Further analysis revealed that body mass index and
maximum ﬂow rate were two independent factors that affected
CRP levels in women [29].
Urinary inﬂammatory biomarkers might also be elevated in
patients with OAB as well as in those with IC/BPS. Recent investi-
gation of urinary chemokines in patients with OAB also showed
increases in monocyte chemotactic protein-1 (MCP-1) and some
proinﬂammatory cytokines such as tumor necrosis factor-a (TNF-
a), granulocyte colony-stimulating factor, and epidermal growth
factor (EGF). In addition, IC/BPS involves an aberrant differentiation
program in the bladder urothelium that leads to altered synthesis
of several proteoglycans, cell adhesion and tight junction proteins,
and bacterial defense molecules such as GP51. These ﬁndings led to
the rationale for searching for potential clusters of urinary
biomarkers to detect IC/BPS in patients with OAB and frequency
urgency syndrome [30]. The biomarkers that have been the focus of
the most research are antiproliferative factor, EGF, heparin-binding
epidermal growth factor, glycosaminoglycans, and bladder nitric
oxide [31].
5. Urinary proteomics in the differential diagnosis between
OAB and IC/BPS
In addition to these urothelial defense molecules, inﬂammatory
proteins in the urine have been found to have important roles in the
pathogenesis of IC/BPS. A pilot study of urinary cytokines revealed
elevated levels of chemokines relevant for chemotaxis of eosino-
phils and monocytes, and activation of mast cells in the urine of
patients with IC/BPS. Chemokines are chemotactic cytokines that
belong to a family of small secreted glycoproteins with a molecular
weight of 7e10 kDa with more than 50 ligands that interact with
multiple receptors. Chemokines exert their effects through inter-
action with seven transmembrane-spanning G protein-coupled
receptors and are present on glycosaminoglycans linked to endo-
thelial cell layers [32]. The most important chemokines causing
chemotactic migration of macrophages, eosinophils, and mast cells
belong to the CC family of chemokines distinguished by adjacent
positions of the ﬁrst two cysteines [33]. The chemokines of this
family are MCP-1 (CCL2), macrophage inﬂammatory protein (MIP-
1; CCL4), and eotaxin (CCL11). MCP-1 provokes mast cell activation
and has chemotactic activity for monocytes that mature into
macrophages at the site of inﬂammation [33]. MIP-1 released from
mast cells and macrophages can bind heparin and has inﬂamma-
tory and neutrophil chemokinetic properties [34]. Eotaxin
possesses selective chemotactic activity for eosinophils [35,36].
Chemokines not only induce chemotaxis, but also activation of
these target cells in the bladder and thereby contribute to the
inﬂammatory-induced changes in rheumatoid arthritis, Crohn
disease, and IC/BPS [37].
Analysis of urine from a single void using commercially available
multiplex immunoassays based on Luminex xMAP technology from
Millipore (Billerica, MA, USA) revealed 10-fold to 100-fold elevation
in the levels of MCP-1, MIP-1, and eotaxin in patients with varying
severities of IC/BPS compared with control patients [38]. The
urinary proteome is a potential easily accessible source of
biomarkers for inﬂammatory bladder disorders, including IC/BPS
and OAB. Analysis of multiple urinary proteins is a convenient
approach to monitoring the activation of inﬂammatory cells in the
bladder tissue [39]. Simultaneous analysis of the chemokines MCP-
1, MIP-1, and eotaxin in urine can show a disease-speciﬁc pattern ofIC/BPS with improved sensitivity and speciﬁcity. In addition to
these inﬂammatory proteins, we can also detect other urothelial
defense proteins that have been found to have a close relationship
with the pathogenesis of IC/BPS but are not found in OABs [31].
The urine levels of selected chemokines have been analyzed
based on immunoassays using the speciﬁcity of antibodies [39].
Proteomics based on immunoassays provide speciﬁc detection of
protein at much lower concentrations and are more suited to
quantiﬁcation than two-dimensional gel or other generic pro-
teomic approaches. Conventional immunoassays of each chemo-
kine for individual measurements using enzyme-linked
immunosorbent assay (ELISA) can incur considerable time, cost,
and sample volume, limiting the systematic examination of
multiple biomarkers. The xMAP technology allowsmultiplexing of
analytes in solution with ﬂow cytometry, and studies show that
there is good correlation of cytokine levels measured by ELISA and
multiplex assay [40]. The increased dynamic movement during
antibodyeantigen reactions that occurs in solution may also
increase its assay efﬁciency [41]. Theoretically, the Luminex plat-
form can provide a wider dynamic range than conventional ELISA
methods because of the greater linear range of ﬂuorescence
intensity compared with absorbance [42].
In a recent study, mean urine cytokine/chemokine levels were
higher in OAB-wet than OAB-dry, suggesting a linear relationship
between symptom severity and cytokine levels. This analysis
revealed signiﬁcant elevation of seven key proteins in the urine of
patients with OAB relative to control patients. A greater than 10-
fold elevation in the levels of MCP-1 and the soluble fraction of
the CD40 ligand was measured in patients with OAB, relative to
control patients. At least ﬁvefold elevations were detected in the
levels of MIP-1b, interleukin (IL)-12,p70/p40, IL-5, EGF, and growth-
related oncogene-a compared with control patients. Signiﬁcant
threefold elevation was also noted in the urine levels of soluble IL-
2Ra, and IL-10 in the OAB group [38].
In a cross-sectional study testing the hypothesis that select
chemokines are increased in the urine of patients with IC/BPS,
midstream urinary specimens were collected from 10 patients with
ulcerative and nonulcerative IC/BPS, and from 10 asymptomatic
control patients. Urinary levels of most chemokines/cytokines were
10-fold to 100-fold lower in asymptomatic control patients versus
patients with ulcerative and nonulcerative IC/BPS. Univariate
comparison of eight tested proteins in the ulcerative versus non-
ulcerative groups revealed a signiﬁcant ﬁvefold to 20-fold increase
in C-X-C motif chemokine-10 and -1, IL-6, and NGF [43]. Because
elevated urinary chemokines/cytokines have been noted in patients
with OAB and those with IC/BPS, it will be interesting to investigate
the differences in these levels between these two conditions.
IC/BPS is a difﬁcult disease to diagnose and treat. Objective
information on the disease is only available in patients with end-
organ disease using expensive and invasive procedures such as
cystoscopy and tissue biopsy [44]. Development of biomarkers for
the diagnosis and prediction of IC/BPS progression is therefore
a high priority. Urinary biomarker identiﬁcation using proteome-
wide analysis may provide an unbiased noninvasive and expedi-
tious diagnosis of IC/BPS. Histologic studies done on tissue biopsies
from IC/BPS patients document inﬁltration of mast cells, macro-
phages, and eosinophils as a consistent ﬁnding [45e48].
The general function of chemokines is inﬂammatory cell adhe-
sion and inﬁltration of leukocytes into inﬂammatory foci. Chemo-
kines measured in previous studies could originate in the urine
from both resident and inﬁltrating cells, including leukocytes,
epithelial cells, and detrusor smooth muscle cells [49]. Bladder
biopsies of patients with IC/BPS reported previously have
conﬁrmed the involvement and presence of eosinophils and
macrophages in the urothelium and mast cells in the detrusor.
Table 2
Comparison of urine nerve growth factor and serum nerve growth factor between patients with interstitial cystitis/bladder pain syndrome and control patients [53].
Control (n ¼ 28) IC/BPS (n ¼ 30) p
Age (range) 32.6  1.56 (22e55 ) 51.3  1.87 (22e86) < 0.001
Sex F:17 M:11 F:26 M:4
Urinary NGF (pg/mL) 1.40  0.63 (0.00e13.6) 26.3  11.2 (0.00e270.4) 0.014
Urinary NGF/Cr (pg/mg) 0.02  0.01 (0.00e0.22) 0.69  0.38 (0.00e-9.52) 0.011
Serum NGF (pg/mL) 1.90  0.38 (0.00e5.85) 3.48  0.55 (0.00e18.0) 0.015
Data are expressed as mean  standard error.
Cr ¼ creatinine; IC/BPS ¼ interstitial cystitis/bladder pain syndrome; NGF ¼ nerve growth factor.
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results showing increased urinary eosinophil cationic protein in the
urine of patients with IC/BPS [10,50,51]. Mast cells have been
considered crucial effector cells for the immune response impli-
cated in the pathogenesis of IC/BPS [9].
6. Serum biomarkers for OAB and IC/PBS
Previous study of serum NGF levels in patients with OAB and IC/
BPS revealed that serum NGF levels were signiﬁcantly elevated in
patients with OAB compared with control patients. Urinary NGF/
creatinine (Cr) levels were signiﬁcantly elevated in patients with
OAB compared with control patients. Serum NGF levels were
signiﬁcantly correlated with urinary NGF and NGF/Cr levels in
patients with OAB. There was no signiﬁcant difference in serum
NGF levels between OAB-dry and OAB-wet. Increased serum and
urinary NGF levels in patients with OAB refractory to anti-
muscarinic treatment suggest these bladder disorders might be
caused by chronic inﬂammation [52]. Interestingly, we also found
that serum NGF was elevated in patients with IC/BPS. The mean
serumNGF level was higher in patients with IC/BPS (3.48 0.55 pg/
mL) than in control patients (1.90  0.38 pg/mL; p ¼ 0.015). No
signiﬁcant correlation was found between the serum and urinary
NGF levels in patients with IC/BPS. However, the clinical charac-
teristics and medical comorbidities did not show signiﬁcant
differences between patients with IC/BPS with high and low serum
NGF levels [53] (Table 2). These results suggest that although
chronic inﬂammation is involved in both OAB and IC/BPS, the
underlying pathophysiology for the phenotype presentation might
be different. Investigation of serum chemokine/cytokine levels
might provide a differentiation between these two bladder
disorders.
Recent investigations have linked OAB with neurogenic
inﬂammation. Neurotrophic factors have been implicated in the
pathophysiologic mechanisms underlying the sensitization of
bladder afferent nerves. NGF, initially described as a prototypical
trophic factor in the development of sensory and sympathetic
innervation, has emerged as a complex regulator of neural plas-
ticity along the micturition pathways. Hepatocyte growth factor
(HGF), a novel neurotrophic factor, also can promote neuronal
survival and growth. In our previous studies, serum and urinary
NGF levels were demonstrated to increase in patients with OAB.
Therefore, the expression of serum HGF and NGF, and suburothelialTable 3
Serum cytokine levels between patients with overactive bladder and control patients [5
Control (n ¼ 26)
Age 32.4  1.56 (22e55)
Sex F:16 M:10
HGF (pg/mL) 104.5  11.39 (4.24e267.39)
NGF (pg/mL) 2.78  0.22 (1.0e5.85)
PGP9.5 0.37  0.059 (n ¼ 5)
Mean  standard error (range).
HGF ¼ hepatocyte growth factor; NGF ¼ nerve growth factor; OAB ¼ overactive bladderneuron marker PGP9.5 was investigated in patients with OAB. The
results of serum adipokine assay showed both serum HGF and
serum NGF levels were signiﬁcantly higher in patients with OAB
than in control patients [54] (Table 3). There was a signiﬁcant
correlation between serum HGF and serum NGF levels. Although
the patients with OAB were older then the control patients, neither
serumHGF nor NGF correlatedwith age. Patients with OAB also had
higher expression of the mucosal neuron marker PGP9.5 than
control patients.
HGF is a strong neurotrophic factor that promotes cell survival
and proliferation. Some studies have reported that HGF cooper-
ates with NGF to enhance the growth of neurons in vitro. In our
study, both serum HGF and NGF levels were high and were
signiﬁcantly correlated with each other in patients with OAB. The
PGP9.5 suburothelial neuron marker expression in all of the
patients with OAB was signiﬁcantly higher than in the control
patients, suggesting nerve ﬁbers were increased in the bladder
mucosa of patients with OAB. Our recent studies have also
demonstrated that patients with OAB have higher expression of
serum and urinary NGF than control patients, indicating that HGF
has neurotrophic properties. Elevation of serum HGF and NGF in
patients with OAB is associated with an increase in PGP9.5
expression, which suggests systemic neurotrophic factor elevation
induces increases in nerve ﬁbers in the suburothelium of the
bladder, which might play a role in urgency and frequency sensory
disorder in patients with OAB.
Cytokines and chemokines play crucial roles in the pathogenesis
of several chronic inﬂammatory diseases. The upregulated proﬁle
of serum IL-1b, IL-6, TNF-a, and IL-8 levels in patients with IC/BPS
might potentially have a prognostic role and/or serve as a tool in
choosing a proper therapeutic agent for treatment. One recent
study revealed that serum proinﬂammatory cytokines (IL-1b, IL-6,
TNF-a) and chemokine (IL-8) levels were signiﬁcantly higher in
the serum of patients with IC/BPS than control patients [55]
(Table 4). Although the patients with IC/BPS were older than the
control patients, these serum cytokine/chemokine levels were not
correlatedwith age. A signiﬁcant correlationwas found between IL-
1b and IL-8, IL-6 and CRP, IL-6 and IL-8, and IL-6 and TNF-a in IC/BPS
serum samples. Increased expression of the proinﬂammatory
cytokines (IL-1b, IL-6, TNF-a) and chemokine (IL-8) in the serum of
patients with IC/BPS patients that not only mast cell activation but
also some other inﬂammatory mediators play important roles in
the pathogenesis of IC/BPS.4].
OAB (n ¼ 30) p
61.0  1.59 (39e73) <0.0001
F: 17 M: 13
193.6  17.72 (50.11e430.57) <0.0001
3.88  0.60 (1.70e17.54) 0.04
0.54  0.06 (n ¼ 10) 0.03
.
Table 4
Expression of serum interleukin-1b, interleukin-6, tumor necrosis factor-a, and
interleukin-8 in patients with interstitial cystitis/bladder pain syndrome and control
patients [55].
Controls (n ¼ 26) IC/BPS (n ¼ 30) p
Sex F:16 M:10 F:26 M:4
Age 32.4  1.56 (22e55) 50.6  2.68 (24e86) <0.0001
IL-1b (pg/mL) 1.64  0.47 (0.00e6.08) 6.45  0.71 (2.77e23.96) <0.0001
IL-6 (pg/mL) 0.79  0.21 (0.00e3.67) 1.52  0.24 (0.00e6.14) <0.0001
TNF-a (pg/mL) 0.91  0.17 (0.00e4.64) 2.63  0.60 (0.62e13.70) <0.0001
IL-8 (pg/mL) 1.45  0.21 (0.00e4.09) 3.23  0.48 (0.00e15.08) <0.0001
Mean  standard error (range).
IC/BPS ¼ interstitial cystitis/bladder pain syndrome; IL ¼ interleukin; TNF ¼ tumor
necrosis factor.
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Analysis of multiple urinary proteins and serum cytokines is
a convenient approach to monitoring the activation of inﬂam-
matory cells in the bladder tissue. Differences in urinary proteins
and serum cytokines might provide a diagnostic basis for IC/BPS
and could be a tool for the differential diagnosis between IC/BPS
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